Wall Street Zen upgraded shares of Omeros (NASDAQ:OMER – Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday.
A number of other research analysts have also commented on the company. HC Wainwright upped their target price on Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. D. Boral Capital reiterated a “buy” rating and set a $36.00 price target on shares of Omeros in a research note on Tuesday, January 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.
Get Our Latest Research Report on Omeros
Omeros Price Performance
Omeros (NASDAQ:OMER – Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported $3.14 EPS for the quarter, beating the consensus estimate of ($0.55) by $3.69. On average, equities research analysts anticipate that Omeros will post -3.09 EPS for the current year.
Insiders Place Their Bets
In other news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 12.90% of the company’s stock.
Hedge Funds Weigh In On Omeros
Several hedge funds and other institutional investors have recently modified their holdings of the stock. UBS Group AG boosted its stake in Omeros by 213.5% in the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after buying an additional 1,513,893 shares in the last quarter. Vanguard Group Inc. raised its stake in Omeros by 19.9% during the fourth quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock worth $68,929,000 after acquiring an additional 666,357 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Omeros by 1,201.1% during the third quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock valued at $1,706,000 after acquiring an additional 384,168 shares during the period. State Street Corp lifted its holdings in shares of Omeros by 26.9% during the fourth quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock valued at $27,025,000 after acquiring an additional 333,798 shares during the period. Finally, Two Sigma Investments LP boosted its stake in shares of Omeros by 39.3% in the 3rd quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock valued at $3,827,000 after purchasing an additional 263,095 shares in the last quarter. Institutional investors own 48.79% of the company’s stock.
Key Omeros News
Here are the key news stories impacting Omeros this week:
- Positive Sentiment: Omeros says it has reached a profitability milestone as part of a strategic shift toward commercialization and partnerships, which management says should improve cash flow and de-risk the business. Omeros Reaches Profitability Milestone Amid Strategic Shift
- Positive Sentiment: HC Wainwright raised near-term EPS estimates for multiple 2026 quarters and lifted FY2026/FY2027 forecasts, while keeping a Buy rating and a $40 price target — a bullish analyst stance that supports higher share valuations. HC Wainwright raises estimates and reiterates Buy, $40 PT
- Positive Sentiment: Q4 results were stronger than expected (company-reported EPS beat and a licensing/deal with Novo Nordisk cited as boosting Q4), providing immediate revenue/earnings proof points that likely pushed the stock higher. Omeros rises as Novo deal boosts Q4 earnings
- Positive Sentiment: Unusually large call-option purchases were reported, signaling bullish positioning by traders and adding short-term upside pressure. Traders Purchase Large Volume of Call Options on Omeros
- Neutral Sentiment: Several analyst and market-commentary pieces outline the bull case ahead of Q1 commercial updates and provide earnings-call detail — useful for context but not immediate catalysts on their own. Omeros: Making The Bull Case On Q4 Earnings
- Neutral Sentiment: Earnings call transcript and summaries are available for deeper detail on guidance and commercialization plans; these will matter when management discusses Q1 commercial progress. Q4 2025 Earnings Call Transcript
- Negative Sentiment: HC Wainwright trimmed several longer-term EPS estimates (FY2028–FY2030), lowering some multi-year upside expectations — a signal that while near-term outlook improved, longer-term model risk remains. HC Wainwright trims long-term EPS forecasts
Omeros Company Profile
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Further Reading
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
